Valerio Therapeutics clinical trials
Also known as Onxeo, BioAlliance.
The registry lists 27 studies whose lead sponsor is Valerio Therapeutics or one of 2 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 17, 2025.
Our grouping of 3 registry names, not the registry’s. See them and correct one ↓
- 27studies on the registry
- 0open to participants now
What it is testing
The drugs Valerio Therapeutics’ studies test, most studies first; none is open now — 7 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 9
- 0 open · 3
- Dexrazoxane2 in phase 30 open · 2
- 0 open · 2
- 0 open · 1
- Doxorubicin1 in phase 30 open · 1
- 0 open · 1
All 27 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 607
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 10 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Valerio Therapeutics.
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid TumorsTerminatedNCT06257758Phase 1/2
- Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid TumorsCompletedNCT05700669Phase 1/2
- AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid TumorsCompletedNCT03579628Phase 1
- Safety of Intranodal ECI-006 in Melanoma PatientsTerminatedNCT03394937Phase 1
Sponsor listed in the registry: eTheRNA immunotherapies · eTheRNA immunotherapies — acquired company within the Valerio Therapeutics group
- Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular CarcinomaCompletedNCT01655693Phase 3
- Efficacy and Safety Study of Clonidine Lauriad® to Treat Oral MucositisCompletedNCT01385748Phase 2
- DNA Repair Inhibitor & Irradiation on MelanomaCompletedNCT01469455Phase 1
Sponsor listed in the registry: DNA Therapeutics · First submitted before DNA Therapeutics became part of Valerio Therapeutics
- Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy VolunteersCompletedNCT02548806Phase 1
- A Clinical Trial on Topotect® (Dexrazoxane) in the Treatment of Accidental Extravasation of AnthracyclinesCompletedNCT00548704Phase 2/3
- Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of AnthracyclinesCompletedNCT00548561Phase 2/3
- A Study to Assess APO866 for the Treatment of Advanced MelanomaCompletedNCT00432107Phase 2
- A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLLCompletedNCT00435084Phase 1/2
- A Phase I Dose Finding Study of APO010 in Patients With Solid TumorsCompletedNCT00437736Phase 1
- Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic MelanomaTerminatedNCT01045915Phase 1
- Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic MelanomaWithdrawnNCT01764009Phase 1/2
- A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse TreatmentCompletedNCT00421889Phase 1/2
- Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive TherapyCompletedNCT00878722Phase 1/2
- Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown PrimaryCompletedNCT00873119Phase 2
- A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue SarcomasCompletedNCT00878800Phase 1/2
- A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell LymphomasTerminatedNCT00274651Phase 2
- A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple MyelomaTerminatedNCT00431340Phase 2
- A Study of APO866 for the Treatment of Cutaneous T-cell LymphomaCompletedNCT00431912Phase 2
- Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsCompletedNCT00413322Phase 1
- Study of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaCompletedNCT00413075Phase 1
- Clinical Trial of PXD101 in Patients With Advanced Multiple MyelomaCompletedNCT00131261Phase 2
- Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV PatientsCompletedNCT00390780Phase 3
- Phase 3 Clinical Study for the Treatment of Cold SoreCompletedNCT00769314Phase 3